Inhibition of Monkeypox virus replication by RNA interference

Virology Journal

Volumn 6, Issue , 2009, Pages

  Alkhalil, Abdulnaser ^a   Strand, Sarah ^a   Mucker, Eric ^a   Huggins, John W ^a   Jahrling, Peter B ^b   Ibrahim, Sofi M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; ANTIVIRUS AGENT;

ANIMAL CELL; ARTICLE; BIOINFORMATICS; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ESSENTIAL GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE POOL; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; IN VITRO STUDY; MONKEYPOX; MONKEYPOX VIRUS; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRUS ENTRY; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE; ANIMAL; CERCOPITHECUS; DRUG EFFECT; GENETICS; VERO CELL;

MONKEYPOX VIRUS; MOROCCAN PEPPER VIRUS; ORTHOPOXVIRUS; POXVIRIDAE; VARIOLA VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; MONKEYPOX VIRUS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VERO CELLS; VIRUS REPLICATION;

EID: 72849130014     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-188     Document Type: Article

References (46)

1. A pox-like disease in cynomolgus monkeys. P Von Magnus EK Andersen KB Petersen A Birch-Andersen, Acta Pathol Microbiol Scand 1959 46 156 176
2. Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. SS Marennikova EM Seluhina NN Mal'ceva KL Cimiskjan GR Macevic, Bull World Health Organ 1972 46 599 611 4340219
3. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. LA Learned MG Reynolds DW Wassa Y Li VA Olson K Karem LL Stempora ZH Braden R Kline A Likos, et al. Am J Trop Med Hyg 2005 73 428 434 16103616
4. Human monkeypox, 1970-79. JG Breman R Kalisa MV Steniowski E Zanotto AI Gromyko I Arita, Bull World Health Organ 1980 58 165 182 6249508
5. The confirmation and maintenance of smallpox eradication. JG Breman I Arita, N Engl J Med 1980 303 1263 1273 6252467
6. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. E De Clercq, Biochem Pharmacol 2007 73 911 922 10.1016/j.bcp.2006.09.014 17045247
7. Isolation and characterization of cidofovir resistant vaccinia viruses. MN Becker M Obraztsova ER Kern DC Quenelle KA Keith MN Prichard M Luo RW Moyer, Virol J 2008 5 58 18479513 10.1186/1743-422X-5-58 (Pubitemid 351749379)
8. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. G Yang DC Pevear MH Davies MS Collett T Bailey S Rippen L Barone C Burns G Rhodes S Tohan, et al. J Virol 2005 79 13139 13149 16189015 10.1128/JVI.79.20.13139-13149.2005 (Pubitemid 41433232)
9. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. FI Broekema FG Dikkers, Eur Arch Otorhinolaryngol 2008 265 871 879 18458927 10.1007/s00405-008-0658-0
10. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. A Fire S Xu MK Montgomery SA Kostas SE Driver CC Mello, Nature 1998 391 806 811 10.1038/35888 9486653 (Pubitemid 28099681)
11. RNA interference: antiviral weapon and beyond. QC Wang QH Nie ZH Feng, World J Gastroenterol 2003 9 1657 1661 12918096
12. RNAi therapeutics: an update on delivery. T Nguyen EM Menocal J Harborth JH Fruehauf, Curr Opin Mol Ther 2008 10 158 167 18386228
13. A computational study of off-target effects of RNA interference. S Qiu CM Adema T Lane, Nucleic Acids Res 2005 33 1834 1847 15800213 10.1093/nar/gki324 (Pubitemid 41748330)
14. Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. F Valderrama JV Cordeiro S Schleich F Frischknecht M Way, Science 2006 311 377 381 10.1126/science.1122411 16424340
15. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. RS Dave JP McGettigan T Qureshi MJ Schnell G Nunnari RJ Pomerantz, Virology 2006 348 489 497 10.1016/j.virol.2006.01.013 16480752
16. Analysis of the monkeypox virus genome. SN Shchelkunov AV Totmenin PF Safronov MV Mikheev VV Gutorov OI Ryazankina NA Petrov IV Babkin EA Uvarova LS Sandakhchiev, et al. Virology 2002 297 172 194 10.1006/viro.2002.1446 12083817
17. Noise amidst the silence: off-target effects of siRNAs? AL Jackson PS Linsley, Trends Genet 2004 20 521 524 10.1016/j.tig.2004.08.006 15475108
18. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. H Huang Y Chen J Ye, Proc Natl Acad Sci USA 2007 104 18666 18670 18003907 10.1073/pnas.0708423104 (Pubitemid 350210754)
19. In vivo imaging of cidofovir treatment of cowpox virus infection. A Goff N Twenhafel A Garrison E Mucker J Lawler J Paragas, Virus Res 2007 128 88 98 10.1016/j.virusres.2007.04.014 17524511
20. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. GJ Arts E Langemeijer R Tissingh L Ma H Pavliska K Dokic R Dooijes E Mesic R Clasen F Michiels, et al. Genome Res 2003 13 2325 2332 12975310 10.1101/gr.1332603 (Pubitemid 37265998)
21. Knocking down disease with siRNAs. DM Dykxhoorn J Lieberman, Cell 2006 126 231 235 10.1016/j.cell.2006.07.007 16873051
22. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. D De Paula MV Bentley RI Mahato, RNA 2007 13 431 456 17329355 10.1261/rna.459807 (Pubitemid 46509424)
23. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Primary percutaneous vaccination. JD Cherry K McIntosh JD Connor AS Benenson DW Alling UT Rolfe WA Todd JE Schanberger Mattheis, J Infect Dis 1977 135 145 154 188951
24. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. EL Cooney AC Collier PD Greenberg RW Coombs J Zarling DE Arditti MC Hoffman SL Hu L Corey, Lancet 1991 337 567 572 10.1016/0140-6736(91)91636-9 1671940
25. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. DF Smee MK Wandersee KW Bailey KY Hostetler A Holy RW Sidwell, Antivir Chem Chemother 2005 16 203 211 16004083
26. Cidofovir in the treatment of poxvirus infections. E De Clercq, Antiviral Res 2002 55 1 13 10.1016/S0166-3542(02)00008-6 12076747
27. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. RS Kornbluth DF Smee RW Sidwell V Snarsky DH Evans KY Hostetler, Antimicrob Agents Chemother 2006 50 4038 4043 16982794 10.1128/AAC.00380-06 (Pubitemid 44865147)
28. Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. BJ Geiss TC Pierson MS Diamond, Virol J 2005 2 53 15985182 10.1186/1743-422X-2-53 (Pubitemid 41124567)
29. Inhibition of herpes simplex virus type 1 by small interfering RNA. YQ Zhang W Lai H Li G Li, Clin Exp Dermatol 2008 33 56 61 17979991
30. Targeted Delivery of siRNA. S Oliveira G Storm RM Schiffelers, J Biomed Biotechnol 2006 2006 63675 17057365
31. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. E Song P Zhu SK Lee D Chowdhury S Kussman DM Dykxhoorn Y Feng D Palliser DB Weiner P Shankar, et al. Nat Biotechnol 2005 23 709 717 10.1038/nbt1101 15908939
32. Targeted mutation of the CREB gene: compensation within the CREB/ATF family of transcription factors. E Hummler TJ Cole JA Blendy R Ganss A Aguzzi W Schmid F Beermann G Schutz, Proc Natl Acad Sci USA 1994 91 5647 5651 8202542 10.1073/pnas.91.12.5647 (Pubitemid 24174385)
33. Large-scale copy number polymorphism in the human genome. J Sebat B Lakshmi J Troge J Alexander J Young P Lundin S Maner H Massa M Walker M Chi, et al. Science 2004 305 525 528 10.1126/science.1098918 15273396
34. Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells. GD Spotts SR Hann, Mol Cell Biol 1990 10 3952 3964 2196440
35. Regulation of orthopoxvirus gene expression. B Moss, Curr Top Microbiol Immunol 1990 163 41 70 2242681
36. Poxvirus DNA-dependent RNA polymerase. JR Kates BR McAuslan, Proc Natl Acad Sci USA 1967 58 134 141 5231593 10.1073/pnas.58.1.134
37. Induction of cytoplasmic ribonucleic acid (RNA) synthesis in vaccinia-infected LM cells during inhibition of protein synthesis. WH Munyon S Kit, Virology 1966 29 303 309 10.1016/0042-6822(66)90037-7 5949673
38. Inhibition of virus replication by RNA interference. PC Haasnoot D Cupac B Berkhout, J Biomed Sci 2003 10 607 616 10.1007/BF02256311 14576463
39. Vaccinia virus transcription. SS Broyles, J Gen Virol 2003 84 2293 2303 10.1099/vir.0.18942-0 12917449
40. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. JC Hsiao CS Chung W Chang, J Virol 1999 73 8750 8761 10482629
41. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. CS Chung JC Hsiao YS Chang W Chang, J Virol 1998 72 1577 1585 9445060
42. RNAi in human cells: basic structural and functional features of small interfering RNA. YL Chiu TM Rana, Mol Cell 2002 10 549 561 10.1016/S1097- 2765(02)00652-4 12408823
43. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. S Vigne R Germi S Duraffour S Larrat G Andrei R Snoeck D Garin JM Crance, Antivir Ther 2008 13 357 368 18572748
44. Inhibition of herpesvirus-6B RNA replication by short interference RNAs. JS Yoon SH Kim MC Shin SK Hong YT Jung IG Khang WS Shin CC Kim SY Paik, J Biochem Mol Biol 2004 37 383 385 15469723
45. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. D Shin SI Kim M Kim M Park, Virus Res 2006 119 146 153 10.1016/j.virusres.2005.12.012 16443303
46. Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. FL Schuster GS Visvesvara, J Clin Microbiol 1996 34 385 388 8789020